



Poster will be available at the time of presentation at the ASCO
Gastrointestinal Cancers Symposium: 7:00 a.m. PT, January 24, 2025



—◆ Visit us at:

ASCO
Gastrointestinal
Cancers
Symposium

January 23-25, 2025
Moscone West • San Francisco, CA

Upcoming poster presentation:

Results from a phase 2 study of triplet blockade of the IL-27, PD-(L)1, and VegF pathways with casdozokitug (casdozo, CHS-388) in combination with atezolizumab (atezo) and bevacizumab (bev) in patients with unresectable, locally advanced or metastatic hepatocellular carcinoma (uHCC)

Friday, January 24, 2025 • 11:30 am – 1:00pm PT •